Novo to pay up to $2.6 billion to China's Hengrui for rights to weight-loss pill ↧ ↧ Novo to pay up to $2.6 billion to China's Hengrui for rights to wei... Novo Nordisk will pay up to $2.6 billion to Jiangsu Hengrui Pharmaceuticals for the rights to an experimental weight-loss pill, expanding its pipeline through a second GLP-1 treatment deal with a Chinese partner.
published
Novo to pay up to $2.6 billion to China's Hengrui for rights to weight-loss pill ↧
Open the original public source →
Latest documented BWB result
See Billy's timestamped results and follow-through.
Review the latest gains posts, original timestamps, and proof images published by Banking With Billy.
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.